

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

21-880

APPROVED LABELING

1 **REVLIMID[®] (lenalidomide)**

2 5 mg & 10 mg capsules

3 **WARNINGS:**

- 4 1. **POTENTIAL FOR HUMAN BIRTH DEFECTS**
5 2. **HEMATOLOGIC TOXICITY (NEUTROPENIA AND THROMBO-**
6 **CYTOPENIA)**
7 3. **DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM**
8

9 **POTENTIAL FOR HUMAN BIRTH DEFECTS**

10 **WARNING: POTENTIAL FOR HUMAN BIRTH DEFECTS**

11 **LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS**
12 **A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-**
13 **THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN**
14 **DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN**
15 **UNBORN BABY. FEMALES SHOULD BE ADVISED TO AVOID PREGNANCY**
16 **WHILE TAKING REVLIMID[®] (lenalidomide).**

17 **Special Prescribing Requirements**

18 **BECAUSE OF THIS POTENTIAL TOXICITY AND TO AVOID FETAL**
19 **EXPOSURE TO REVLIMID[®] (lenalidomide), REVLIMID[®] (lenalidomide) IS**
20 **ONLY AVAILABLE UNDER A SPECIAL RESTRICTED DISTRIBUTION**
21 **PROGRAM. THIS PROGRAM IS CALLED "REVASSISTSM". UNDER THIS**
22 **PROGRAM, ONLY PRESCRIBERS AND PHARMACISTS REGISTERED WITH**
23 **THE PROGRAM ARE ABLE TO PRESCRIBE AND DISPENSE THE**
24 **PRODUCT. IN ADDITION, REVLIMID MUST ONLY BE DISPENSED TO**
25 **PATIENTS WHO ARE REGISTERED AND MEET ALL THE CONDITIONS OF**
26 **THE REVASSISTSM PROGRAM.**

27 **PLEASE SEE THE FOLLOWING INFORMATION FOR PRESCRIBERS,**
28 **FEMALE PATIENTS, AND MALE PATIENTS ABOUT THIS RESTRICTED**
29 **DISTRIBUTION PROGRAM.**

30 **CELGENE'S REVASSISTSM PROGRAM DESCRIPTION**

31 **Prescribers**

32 **REVLIMID[®] (lenalidomide) will be prescribed only by licensed prescribers who are**
33 **registered in the RevAssistSM program and understand the potential risk of teratogenicity**
34 **if lenalidomide is used during pregnancy.**

35 Effective contraception must be used by patients for at least 4 weeks before beginning
36 REVLIMID[®] therapy, during REVLIMID[®] (lenalidomide) therapy, during dose
37 interruptions and for 4 weeks following discontinuation of REVLIMID[®] (lenalidomide)
38 therapy. Reliable contraception is indicated even where there has been a history of
39 infertility, unless due to hysterectomy or because the patient has been postmenopausal
40 naturally for at least 24 consecutive months. Two reliable forms of contraception must
41 be used simultaneously unless continuous abstinence from heterosexual sexual contact is
42 the chosen method. Females of childbearing potential should be referred to a qualified
43 provider of contraceptive methods, if needed. Sexually mature females who have not
44 undergone a hysterectomy or who have not been postmenopausal naturally for at least 24
45 consecutive months (i.e., who have had menses at some time in the preceding 24
46 consecutive months) are considered to be females of childbearing potential.

47 **Before prescribing REVLIMID[®] (lenalidomide)**, females of childbearing potential
48 should have 2 negative pregnancy tests (sensitivity of at least 50 mIU/mL). The first test
49 should be performed within 10 – 14 days, and the second test within 24 hours prior to
50 prescribing REVLIMID[®] (lenalidomide). A prescription for REVLIMID[®] (lenalidomide)
51 for a female of childbearing potential must not be issued by the prescriber until negative
52 pregnancy tests have been verified by the prescriber.

53 *Male Patients:* It is not known whether lenalidomide is present in the semen of patients
54 receiving the drug. Therefore, males receiving REVLIMID[®] (lenalidomide) must always
55 use a latex condom during any sexual contact with females of childbearing potential even
56 if they have undergone a successful vasectomy.

57 **Once treatment has started and during dose interruptions**, pregnancy testing for
58 females of childbearing potential should occur weekly during the first 4 weeks of use,
59 then pregnancy testing should be repeated every 4 weeks in females with regular
60 menstrual cycles. If menstrual cycles are irregular, the pregnancy testing should occur
61 every 2 weeks. Pregnancy testing and counseling should be performed if a patient misses
62 her period or if there is any abnormality in her pregnancy test or in her menstrual
63 bleeding. REVLIMID[®] (lenalidomide) treatment must be discontinued during this
64 evaluation.

65 Pregnancy test results should be verified by the prescriber and the pharmacist prior to
66 dispensing any prescription.

67 If pregnancy does occur during REVLIMID[®] (lenalidomide) treatment, REVLIMID[®]
68 (lenalidomide) must be discontinued immediately.

69 Any suspected fetal exposure to REVLIMID[®] (lenalidomide) should be reported to the
70 FDA via the MedWatch number at 1-800-FDA-1088 and also to Celgene Corporation at
71 1-888-4CELGEN. The patient should be referred to an obstetrician/gynecologist
72 experienced in reproductive toxicity for further evaluation and counseling.

73 **Female Patients**

- 74 REVLIMID® (lenalidomide) should be used in females of childbearing potential only
75 when the patient MEETS ALL OF THE FOLLOWING CONDITIONS (i.e., she is
76 unable to become pregnant while on lenalidomide therapy):
- 77 • she appears to understand the risks associated with the drug and is thought to be able
78 to reliably carry out instructions.
 - 79 • she is capable of complying with the contraceptive measures, pregnancy testing,
80 patient registration, and patient survey as described in the RevAssistSM program.
 - 81 • she has received both oral and written warnings of the potential risks of taking
82 lenalidomide during pregnancy and of exposing a fetus to the drug.
 - 83 • she has received both oral and written warnings of the risk of possible contraception
84 failure and of the need to use two reliable forms of contraception simultaneously,
85 unless continuous abstinence from heterosexual sexual contact is the chosen method.
86 Sexually mature females who have not undergone a hysterectomy or who have not
87 been postmenopausal for at least 24 consecutive months (i.e., who have had menses at
88 some time in the preceding 24 consecutive months) are considered to be females of
89 childbearing potential.
 - 90 • she acknowledges, in writing, her understanding of these warnings and of the need for
91 using two reliable methods of contraception for 4 weeks prior to beginning
92 lenalidomide therapy, during lenalidomide therapy, during dose interruptions and for
93 4 weeks after discontinuation of lenalidomide therapy.
 - 94 • she has had two negative pregnancy tests with a sensitivity of at least 50 mIU/mL,
95 within 10-14 days and 24 hours prior to beginning therapy.
 - 96 • if the patient is between 12 and 18 years of age, her parent or legal guardian are to
97 read the educational materials and agree to try to ensure compliance with the above.

98 **Male Patients**

- 99 REVLIMID® (lenalidomide) should be used in sexually active males when the PATIENT
100 MEETS ALL OF THE FOLLOWING CONDITIONS:
- 101 • he appears to understand the risks associated with the drug and is thought to be able
102 to reliably carry out instructions.
 - 103 • he is capable of complying with the contraceptive measures that are appropriate for
104 men, patient registration, and patient survey as described in the RevAssistSM program.
 - 105 • he has received both oral and written warnings of the potential risks of taking
106 lenalidomide and exposing a fetus to the drug.

- 107 • he has received both oral and written warnings of the risk of possible contraception
108 failure and that it is unknown whether lenalidomide is present in semen. He has been
109 instructed that he must always use a latex condom during any sexual contact with
110 females of childbearing potential, even if he has undergone a successful vasectomy.
- 111 • he acknowledges, in writing, his understanding of these warnings and of the need to
112 use a latex condom during any sexual contact with females of childbearing potential,
113 even if he has undergone a successful vasectomy. Females of childbearing potential
114 are considered to be sexually mature females who have not undergone a hysterectomy
115 or who have not been postmenopausal for at least 24 consecutive months (i.e., who
116 have had menses at any time in the preceding 24 consecutive months).
- 117 • if the patient is between 12 and 18 years of age, his parent or legal guardian are to
118 read the educational materials and agree to try to ensure compliance with the above.

119 **HEMATOLOGIC TOXICITY (NEUTROPENIA AND THROMBOCYTOPENIA)**

120 **This drug is associated with significant neutropenia and thrombocytopenia in**
121 **patients with del 5q MDS. Eighty percent of patients had to have a dose**
122 **delay/reduction during the major study for the indication. Thirty-four percent of**
123 **patients had to have a second dose delay/reduction. Grade 3 or 4 hematologic**
124 **toxicity was seen in 80% of patients enrolled in the study. Patients on therapy**
125 **should have their complete blood counts monitored weekly for the first 8 weeks of**
126 **therapy and at least monthly thereafter. Patients may require dose interruption**
127 **and/or reduction. Patients may require use of blood product support and/or growth**
128 **factors. (SEE DOSAGE AND ADMINISTRATION)**

129 **DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM**

130 **This drug has demonstrated a significantly increased risk of deep vein**
131 **thrombosis (DVT) and pulmonary embolism (PE) in patients with multiple**
132 **myeloma who were treated with REVLIMID® (lenalidomide) combination therapy.**
133 **Patients and physicians are advised to be observant for the signs and symptoms of**
134 **thromboembolism. Patients should be instructed to seek medical care if they**
135 **develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. It**
136 **is not known whether prophylactic anticoagulation or antiplatelet therapy**
137 **prescribed in conjunction with REVLIMID® (lenalidomide) may lessen the**
138 **potential for venous thromboembolic events. The decision to take prophylactic**
139 **measures should be done carefully after an assessment of an individual patient's**
140 **underlying risk factors.**

141 **You can get the information about REVLIMID® and the RevAssistSM program on**
142 **the internet at www.REVLIMID.com or by calling the manufacturer's toll free**
143 **number 1-888-4CELGEN.**

144 **DESCRIPTION**

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.